CASI Pharmaceuticals (CASIF) Liabilities and Shareholders Equity (2021 - 2025)

CASI Pharmaceuticals has reported Liabilities and Shareholders Equity for 5 years, with the latest figure at $25.6 million in Q4 2025.

• For the quarter ending Q4 2025, Liabilities and Shareholders Equity fell 52.21% year-over-year to $25.6 million; the trailing twelve-month figure through Dec 2025 stood at $81.4 million (down 53.6% YoY), and the FY2025 full-year result was $25.6 million, down 52.21% from the prior year.
• Liabilities and Shareholders Equity for Q4 2025 stood at $25.6 million, up from $24.5 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $138.3 million in Q4 2021, with the low at $40821.0 in Q1 2025.
• Historically, Liabilities and Shareholders Equity has averaged $47.2 million across 5 years, with a median of $42.4 million in 2024.
• The largest YoY upside for Liabilities and Shareholders Equity was 60757.01% in 2025 against a maximum downside of 99.93% in 2025.
• CASI Pharmaceuticals' Liabilities and Shareholders Equity stood at $138.3 million in 2021, then slumped by 30.42% to $96.2 million in 2022, then slipped by 21.79% to $75.3 million in 2023, then retreated by 28.69% to $53.7 million in 2024, then plunged by 52.21% to $25.6 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $25.6 million (Q4 2025), $24.5 million (Q3 2025), and $31.2 million (Q2 2025), per Business Quant data.